Dr. Michael Weiss

Internal Medicine
Kaiser
1425 S Main St, 
Walnut Creek, CA 
Kaiser
1425 S Main St, 
Walnut Creek, CA 

Overview

Michael Weiss is a primary care provider, practicing in Internal Medicine in Walnut Creek, California.

His clinical expertise encompasses Viral Gastroenteritis, Crohn's Disease, Colitis, and Ulcerative Colitis.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 10 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Kaiser
1425 S Main St, Walnut Creek, CA 94596
Other Locations
The Permanente Medical Group Inc
1800 Harrison St Fl 7, Oakland, CA 94612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: February 18, 2026
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase II Randomized, Placebo Controlled, Double-blind, Four Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Crohn's Disease
A Phase II Randomized, Placebo Controlled, Double-blind, Four Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Crohn's Disease
Enrollment Status: Completed
Publish Date: March 15, 2023
Intervention Type: Drug
Study Drug: SHR-0302 JAK Inhibitor
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
The Coflex®COMMUNITY Study: An Observational Study of Coflex® Interlaminar Technology
The Coflex®COMMUNITY Study: An Observational Study of Coflex® Interlaminar Technology
Enrollment Status: Completed
Publish Date: December 24, 2019
Intervention Type: Device
View 9 Less Clinical Trials

2 Total Publications

Patient Outcomes After Minimally Invasive Excision of Lumbar Synovial Cysts, With and Without a Spondylolisthesis, in an Ambulatory Care Center Setting.
Patient Outcomes After Minimally Invasive Excision of Lumbar Synovial Cysts, With and Without a Spondylolisthesis, in an Ambulatory Care Center Setting.
Journal: International journal of spine surgery
Published: July 14, 2022
Similar Doctors
Expertise in
28
conditions
Dr. Michael Albert
Internal Medicine
Expertise in
28
conditions
Dr. Michael Albert
Internal Medicine

The Periscope Group

548 Market St, 
San Francisco, CA 
 (19.9 miles away)
212-937-6400
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Albert is a primary care provider, practicing in Internal Medicine in San Francisco, California. He has been practicing medicine for over 10 years. Dr. Albert is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Nijmegen Breakage Syndrome, Wiskott-Aldrich Syndrome, Autosomal Dominant Hyper IgE Syndrome, Splenectomy, and Spinal Fusion.

Expertise in
18
conditions
Dr. Stephen Luby
Internal Medicine
Expertise in
18
conditions
Dr. Stephen Luby
Internal Medicine

Office

473 Via Ortega # Y2, 
Stanford, CA 
 (33.3 miles away)
650-723-4129
Languages Spoken:
English

Stephen Luby is a primary care provider, practicing in Internal Medicine in Stanford, California. Dr. Luby is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Diarrhea, Parainfluenza, Typhoid Fever, and Salmonella Enterocolitis.

Expertise in
10
conditions
Dr. Gregory Kato
Internal Medicine
Expertise in
10
conditions
Dr. Gregory Kato
Internal Medicine

El Camino Health

2500 Grant Rd, 
Mountain View, CA 
 (36.1 miles away)
408-739-6000
Languages Spoken:
English

Gregory Kato is a primary care provider, practicing in Internal Medicine in Mountain View, California. Dr. Kato is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Endoscopy, and Gastrostomy.

Frequently Asked Questions about Dr. Michael Weiss

How do I make an appointment with Dr. Michael Weiss?

You can book an appointment with Dr. Michael Weiss by calling their office at 925-295-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael Weiss a top-rated expert for Viral Gastroenteritis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael Weiss is classified as an Experienced expert for Viral Gastroenteritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael Weiss specialize in?

While Dr. Michael Weiss is a Internal Medicine, they have specific expertise in Viral Gastroenteritis, Crohn's Disease, and Colitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Michael Weiss participate in research or clinical trials?

Yes. Dr. Michael Weiss has published 2 articles and abstracts on conditions like Viral Gastroenteritis. You can view a list of Dr. Michael Weiss's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weiss's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile